Natera falls as $96 mln patent verdict overturned
25/02/2025 12:20
** Shares of genetic testing firm Natera NTRA.O fall 2.3%
to $154.80 premarket, as a $96 mln jury verdict against rival
CareDx CDNA.O gets overturned
** U.S. District Judge Colm Connolly rules that the patents
Natera accused CareDx of infringing were invalid, dismissing
Natera's 2024 trial win over patent rights in DNA testing
technology for kidney transplants
** Natera plans to appeal the decision and pursue "all
available remedies"
** CareDx's attorney said the decision was "the right
outcome on the law and for organ transplant patients"
** A jury had previously said that CareDx infringed one of
the patents and awarded Natera $96.3 million in damages, but the
judge's decision overturned this verdict
** NTRA more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers